Alzheimer's Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Alzheimer's Disease - Pipeline Review, H2 2016

Alzheimer's Disease - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Alzheimer's Disease - Pipeline Review, H2 2016
Published Aug 10, 2016
1284 pages — Published Aug 10, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Alzheimer's Disease - Pipeline Review, H2 2016, provides an overview of the Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects
- The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by und

  
Source:
Document ID
GMDHC8356IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents272
  List of Tables658
  List of Figures731
Introduction741
  Global Markets Direct Report Coverage741
Alzheimer's Disease Overview751
Therapeutics Development762
  Pipeline Products for Alzheimer's Disease Overview761
  Pipeline Products for Alzheimer's Disease Comparative Analysis771
Alzheimer's Disease Therapeutics under Development by Companies7821
Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes997
Alzheimer's Disease Pipeline Products Glance1064
  Late Stage Products1061
  Clinical Stage Products1071
  Early Stage Products1081
  Unknown Stage Products1091
Alzheimer's Disease Products under Development by Companies11030
Alzheimer's Disease Products under Investigation by Universities/Institutes14010
Alzheimer's Disease Companies Involved in Therapeutics Development150228
  AB Science SA1501
  AbbVie Inc1511
  AC Immune SA1521
  Accera, Inc.1531
  Acelot, Inc.1541
  Actinogen Limited1551
  Acumen Pharmaceuticals, Inc.1561
  Addex Therapeutics Ltd1571
  Affibody AB1581
  AFFiRiS AG1591
  Alector LLC1601
  Alkermes Plc1611
  Allergan Plc1621
  Allinky Biopharma1631
  ALSP, Inc.1641
  Alzhyme Pty Ltd1651
  Alzinova AB1661
  AlzProtect SAS1671
  Amarantus Bioscience Holdings, Inc.1681
  Amgen Inc.1691
  Anavex Life Sciences Corp.1701
  Aphios Corporation1711
  Apodemus AB1721
  Applied Research using OMIC Sciences, S.L.1731
  Araclon Biotech, S.L.1741
  Archer Pharmaceuticals, Inc.1751
  ArmaGen Inc.1761
  Artery Therapeutics, Inc.1771
  AskAt Inc.1781
  Astellas Pharma Inc.1791
  AstraZeneca Plc1801
  Asubio Pharma Co., Ltd.1811
  Ausio Pharmaceuticals, LLC1821
  Avineuro Pharmaceuticals, Inc.1831
  Axon Neuroscience SE1841
  Axovant Sciences Ltd.1851
  Axsome Therapeutics, Inc.1861
  Axxam SpA1871
  Beactica AB1881
  Berg LLC1891
  BioArctic Neuroscience AB1901
  Bioasis Technologies Inc.1911
  Biogen Inc1921
  Biomar Microbial Technologies1931
  Bionature E.A. Ltd.1941
  Boehringer Ingelheim GmbH1951
  Bristol-Myers Squibb Company1961
  Bsim21971
  Cardax Pharmaceuticals, Inc.1981
  Carna Biosciences, Inc.1991
  Celon Pharma Sp. z o.o.2001
  CHA Bio &Diostech Co., Ltd.2011
  Chase Pharmaceuticals Corporation2021
  Clera Inc.2031
  Cognition Therapeutics, Inc.2041
  Cognosci, Inc.2051
  CohBar, Inc.2061
  Connexios Life Sciences Pvt. Ltd.2071
  ContraVir Pharmaceuticals, Inc.2081
  Corium International, Inc.2091
  Coronis Partners Ltd.2101
  Cortice Biosciences, Inc.2111
  Critical Outcome Technologies Inc.2121
  Crossbeta Biosciences B.V.2131
  D-Pharm Ltd.2141
  Daewoong Pharmaceutical Co., Ltd.2151
  Daiichi Sankyo Company, Limited2161
  Daval International Limited2171
  DermaXon, LLC2181
  Dongkook Pharmaceutical Co., Ltd.2191
  Eisai Co., Ltd.2201
  Eli Lilly and Company2211
  Emergent BioSolutions Inc.2221
  EncephRx, Inc.2231
  Endece, LLC2241
  ENKAM Pharmaceuticals A/S2251
  Ensemble Therapeutics Corporation2261
  Ensol Biosciences Inc.2271
  Epigen Biosciences, Inc.2281
  Euroscreen S.A.2291
  Evotec AG2301
  F. Hoffmann-La Roche Ltd.2311
  FORUM Pharmaceuticals Inc.2321
  Genentech, Inc.2331
  Genervon Biopharmaceuticals, LLC2341
  GlaxoSmithKline Plc2351
  GliaCure Inc.2361
  Glialogix, Inc.2371
  Golden Biotechnology Corp.2381
  Grifols, S.A.2391
  H. Lundbeck A/S2401
  Heptares Therapeutics Limited2411
  HitGen LTD2421
  Humanetics Corporation2431
  Ichor Medical Systems, Inc.2441
  Icure Pharmaceutical Inc.2451
  Immungenetics AG2461
  Impel NeuroPharma, Inc.2471
  ImStar Therapeutics Inc.2481
  Inovio Pharmaceuticals, Inc.2491
  IntelGenx Corp.2501
  Intellect Neurosciences, Inc.2511
  Intra-Cellular Therapies, Inc.2521
  INVENT Pharmaceuticals, Inc.2531
  Io Therapeutics, Inc.2541
  Iproteos S.L.2551
  Jeil Pharmaceutical Co., Ltd.2561
  Jiangsu Kanion Pharmaceutical Co., Ltd.2571
  Johnson &Johnson2581
  K-Stemcell Co., Ltd.2591
  Kadmon Corporation, LLC2601
  Kalgene Pharmaceuticals Inc.2611
  Kareus Therapeutics, SA2621
  KineMed, Inc.2631
  Krenitsky Pharmaceuticals Inc.2641
  Kyowa Hakko Kirin Co., Ltd.2651
  Lead Discovery Center GmbH2661
  Les Laboratoires Servier SAS2671
  Lipopharma Therapeutics SL2681
  Living Cell Technologies Limited2691
  Lupin Limited2701
  M3 Biotechnology, Inc.2711
  ManRos Therapeutics2721
  MedDay SA2731
  Medestea Research &Production S.p.A.2741
  MedImmune, LLC2751
  Medisyn Technologies, Inc.2761
  MEDRx Co., Ltd.2771
  Merck &Co., Inc.2781
  Metabolic Solutions Development Company, LLC2791
  Mithridion, Inc.2801
  Mitochon Pharmaceuticals, Inc.2811
  NAL Pharmaceuticals Ltd.2821
  Nanomerics Ltd2831
  Nanotherapeutics, Inc.2841
  Neuralstem, Inc.2851
  Neuraltus Pharmaceuticals, Inc.2861
  Neurim Pharmaceuticals Ltd2871
  Neuro-Sys SAS2881
  Neurodyn Inc.2891
  NeuroGeneration, Inc.2901
  NeuroGenetic Pharmaceuticals, Inc.2911
  NeuroNascent, Inc.2921
  Neuronax SAS2931
  NeurOp, Inc2941
  NeuroPhage Pharmaceuticals, Inc.2951
  Neuropore Therapies, Inc.2961
  Neurotez, Inc.2971
  New World Laboratories, Inc.2981
  nLife Therapeutics, S.L.2991
  NLS Pharma Group3001
  Novartis AG3011
  NsGene A/S3021
  Oligomerix, inc.3031
  ORPHIT3041
  Oryzon Genomics SA3051
  Otsuka Holdings Co., Ltd.3061
  P2D Bioscience3071
  Pain Therapeutics, Inc.3081
  Palumed S.A.3091
  Panacea Pharmaceuticals, Inc.3101
  PeptiDream Inc.3111
  Peptron, Inc.3121
  Pfizer Inc.3131
  PharmaKure Limited3141
  PharmatrophiX, Inc.3151
  Pharmaxis Limited3161
  Pharnext SA3171
  Phenomenome Discoveries, Inc.3181
  Pivot Pharmaceuticals Inc3191
  Prevacus, Inc.3201
  Probiodrug AG3211
  Progenra, Inc.3221
  ProMIS Neurosciences Inc.3231
  ProQR Therapeutics N.V.3241
  Proteome Sciences Plc3251
  Proteostasis Therapeutics, Inc.3261
  QR Pharma, Inc.3271
  Radius Health, Inc.3281
  Regenera Pharma Ltd.3291
  reMYND NV3301
  Resverlogix Corp.3311
  Retrotope, Inc3321
  ReXceptor Inc.3331
  Rodos BioTarget GmbH3341
  Sage Therapeutics, Inc.3351
  SanBio, Inc.3361
  Saneron CCEL Therapeutics, Inc.3371
  Saniona AB3381
  Sanofi3391
  Selvita S.A.3401
  SeneXta Therapeutics SA3411
  Serometrix, LLC3421
  SignPath Pharma Inc3431
  Signum Biosciences, Inc.3441
  Simcere Pharmaceutical Group3451
  SK Biopharmaceuticals Co., Ltd.3461
  SOM Innovation Biotech SL3471
  Spectrum Pharmaceuticals, Inc.3481
  Stemedica Cell Technologies, Inc.3491
  Sumitomo Dainippon Pharma Co., Ltd.3501
  Summit Therapeutics Plc3511
  Suven Life Sciences Ltd.3521
  T3D Therapeutics, Inc.3531
  Takeda Pharmaceutical Company Limited3541
  TauRx Therapeutics Ltd.3551
  TechnologieAllianz e. V.3561
  TechnoPhage SA3571
  Teijin Pharma Limited3581
  Teikoku Pharma USA, Inc.3591
  Tetra Discovery Partners LLC3601
  Thera Neuropharma Inc3611
  Therapix Biosciences Ltd3621
  Tiziana Life Sciences Plc3631
  Toyama Chemical Co., Ltd.3641
  Transition Therapeutics Inc.3651
  Treventis Corporation3661
  TyrNovo Ltd.3671
  UCB S.A.3681
  Varinel, Inc.3691
  Vaxine Pty Ltd3701
  Virobay Inc.3711
  Vitae Pharmaceuticals, Inc.3721
  Voyager Therapeutics, Inc.3731
  vTv Therapeutics Inc3741
  Vybion, Inc.3751
  Wellstat Therapeutics Corporation3761
  Zhejiang Hisun Pharmaceutical Co., Ltd.3771
Alzheimer's Disease Therapeutics Assessment37856
  Assessment by Monotherapy Products3781
  Assessment by Combination Products3791

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Alzheimer's Disease - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alzheimer-s-Disease-Pipeline-Review-H2-2016-2088-16364>
  
APA:
Global Markets Direct - Market Research. (2016). Alzheimer's Disease - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alzheimer-s-Disease-Pipeline-Review-H2-2016-2088-16364>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.